Abusaria Ravindra, Yadav Chinmai, Jain Vinod, Kachhawa Dilip, Rao Pankaj, Lamoria Anand
Department of Dermatology, Government SK Hospital, Sikar, Rajasthan, India.
Department of Dermatology, Dr. Sampurnanand Medical College, Jodhpur, Rajasthan, India.
Indian Dermatol Online J. 2024 Aug 16;15(5):812-816. doi: 10.4103/idoj.idoj_394_23. eCollection 2024 Sep-Oct.
Warts are benign epidermal proliferations, caused by infection of keratinocytes with human papillomavirus (HPV). Auto implantation and intralesional mumps, measles, and rubella (MMR) vaccine are novel methods of immunotherapy for treating periungual and palmoplantar warts. They act by stimulating the patient's immune system; this clears not only the local warts but also distant warts with lesser side effects.
We conducted this study to compare the efficacy and safety of both methods in treating periungual and palmoplantar warts.
A total of 160 patients were randomly allocated into two groups of 80 patients. Group A was treated with 0.3 mL of intralesional MMR vaccine at an interval of 3 weeks or for a maximum of three sittings, and Group B was treated with auto implantation.
At the end of therapy, the result was better in group A (MMR vaccine) as 86% of cases yielded an excellent response as compared to 71% in group B (auto implantation). The recurrence rate was 5% in group A and 4% in group B. There were no serious side effects in both groups with pain during injection (70%) in group A and swelling at the recipient site (8%) in group B being the most common side effect.
Both MMR and auto implantation had significant response rates. But MMR was faster and better.
疣是良性表皮增生,由人乳头瘤病毒(HPV)感染角质形成细胞引起。自身接种和病灶内注射腮腺炎、麻疹和风疹(MMR)疫苗是治疗甲周疣和掌跖疣的新型免疫疗法。它们通过刺激患者的免疫系统起作用;这不仅能清除局部疣体,还能清除远处的疣体,且副作用较小。
我们开展本研究以比较这两种方法治疗甲周疣和掌跖疣的疗效和安全性。
总共160例患者被随机分为两组,每组80例。A组每隔3周接受0.3 mL病灶内MMR疫苗治疗,最多治疗三次;B组接受自身接种治疗。
治疗结束时,A组(MMR疫苗)效果更好,86%的病例产生了极佳反应,而B组(自身接种)为71%。A组复发率为5%,B组为4%。两组均未出现严重副作用,A组最常见的副作用是注射时疼痛(70%),B组是受种部位肿胀(8%)。
MMR疫苗和自身接种均有显著的有效率。但MMR疫苗起效更快且效果更好。